What is a stock summary page? Click here for an overview.
Business Description
Esperion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29664W1053
Share Class Description:
ESPR: Ordinary SharesCompare
Compare
Traded in other countries / regions
ESPR.USA0IIM.UK0ET.Germany Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2013-06-26Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | -1.13 | |||||
| Debt-to-Equity | -0.77 | |||||
| Debt-to-EBITDA | 39.32 | |||||
| Interest Coverage | 0.92 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -5.02 | |||||
| Beneish M-Score | -0.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -13.2 | |||||
| 3-Year FCF Growth Rate | 75.9 | |||||
| 3-Year Book Growth Rate | 15 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.86 | |||||
| 9-Day RSI | 32.98 | |||||
| 14-Day RSI | 30.98 | |||||
| 3-1 Month Momentum % | -20 | |||||
| 6-1 Month Momentum % | -20 | |||||
| 12-1 Month Momentum % | -15.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.37 | |||||
| Quick Ratio | 0.99 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 423.29 | |||||
| Days Sales Outstanding | 68.41 | |||||
| Days Payable | 206.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -47.6 | |||||
| Shareholder Yield % | -60.36 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.36 | |||||
| Operating Margin % | 16.37 | |||||
| Net Margin % | -15.57 | |||||
| FCF Margin % | -7.21 | |||||
| ROA % | -16.28 | |||||
| ROIC % | 74.64 | |||||
| 3-Year ROIIC % | 442.87 | |||||
| ROC (Joel Greenblatt) % | 104.78 | |||||
| ROCE % | 5.51 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 44.53 | |||||
| PE Ratio without NRI | 22.44 | |||||
| PS Ratio | 0.49 | |||||
| EV-to-EBIT | 43.63 | |||||
| EV-to-Forward-EBIT | -12.55 | |||||
| EV-to-EBITDA | 43.26 | |||||
| EV-to-Forward-EBITDA | -12.55 | |||||
| EV-to-Revenue | 0.99 | |||||
| EV-to-Forward-Revenue | 1.06 | |||||
| EV-to-FCF | -13.66 | |||||
| Price-to-GF-Value | 0.32 | |||||
| Earnings Yield (Greenblatt) % | 2.29 | |||||
| FCF Yield % | -13.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ESPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Esperion Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 332.314 | ||
| EPS (TTM) ($) | -0.25 | ||
| Beta | 1.41 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.24 | ||
| Volatility % | 67.9 | ||
| 14-Day RSI | 30.98 | ||
| 14-Day ATR ($) | 0.104986 | ||
| 20-Day SMA ($) | 1.099545 | ||
| 12-1 Month Momentum % | -15.58 | ||
| 52-Week Range ($) | 0.8191 - 3.94 | ||
| Shares Outstanding (Mil) | 198.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Esperion Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Esperion Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Esperion Therapeutics Inc Frequently Asked Questions
What is Esperion Therapeutics Inc(ESPR)'s stock price today?
The current price of ESPR is $0.92. The 52 week high of ESPR is $3.94 and 52 week low is $0.82.
When is next earnings date of Esperion Therapeutics Inc(ESPR)?
The next earnings date of Esperion Therapeutics Inc(ESPR) is 2025-05-06.
Does Esperion Therapeutics Inc(ESPR) pay dividends? If so, how much?
Esperion Therapeutics Inc(ESPR) does not pay dividend.
Guru Commentaries on NAS:ESPR
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers